MYND — MYND Life Sciences Income Statement
0.000.00%
Last trade - 00:00- CA$3.35m
- CA$6.35m
- 18
- 37
- 69
- 36
Annual income statement for MYND Life Sciences, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | ||||
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 0.056 | 4.4 | 3.71 | 1.56 |
| Operating Profit | -0.056 | -4.4 | -3.71 | -1.56 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -0.056 | -4.54 | -3.7 | -1.52 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.056 | -4.37 | -3.57 | -1.52 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.056 | -4.37 | -3.57 | -1.52 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.056 | -4.37 | -3.57 | -1.52 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.001 | -0.096 | -0.077 | -0.053 |